fairli valu sentiment heat
page full analyst note feb
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research feb
estim oct
price data feb
rate updat feb
currenc amount express
valuat growth profit
methodolog valu compani
vertex pharmaceut best known
discov incivek blockbust hepat hcv drug
firm futur tie robust cystic fibrosi cf portfolio
approv treatment kalydeco orkambi well addit
pipelin asset expect creat domin franchis
kalydeco success launch vertex
well-posit cf genet disord affect approxim
peopl world-wide character progress deadli
declin lung function number target patient
small kalydeco abl command six-figur price
disease-modifi drug seriou orphan indic drug
launch price close treatment
less cf suffer certain genet mutat
name gate mutat despit aggress price
major patient popul alreadi captur
vertex pipelin strategi develop drug known
corrector work combin kalydeco order treat
genet subtyp make larger portion cf patient
orkambi combo regimen approv
treat peopl common cf mutat
homozyg repres half cf popul
anticip vertex reach billion-plu peak sale
patient segment alon help eventu
next-gener combo approv impress result
triplet combin pave way vertex next-biggest
opportun difficult-to-treat het/min cf patient segment
third total cf popul
pois
dramat chang treatment cf earn firm
domin posit market world-wide chronic natur
therapi limit competit horizon heighten
market attract given posit market dynam
think vertex cf program could grow billion within
forecast period
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
discov develop small-molecul drug
treatment seriou diseas firm key drug kalydeco
orkambi cystic fibrosi also sever mid- late-stag product
target market vertex success develop commerci
two hiv proteas inhibitor outlicens glaxosmithklin
vertex pipelin also includ therapi treatment cancer pain
inflammatori diseas influenza
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
share fairli valu sentiment heat feb
vertex cystic fibrosi powerhous finish year
solid growth augment slightli fourth-
million larg fell line expect
anticip major chang per share fair valu
estim view share appear fairli valu
gradual build investor enthusiasm past
month two anticip catalyst first
progress two combo drug regimen pivot trial
announc conjunct fourth-quart result
second expect approv vertex next-gener
orkambi tezacaftor kalydeco cf patient two
copi mutat materi
end februari fda pdufa date feb vertex
lockstep execut cf develop program
entrench moat creat solid foundat
build post-cf drug portfolio
kalydeco monotherapi continu benefit strong
patient uptak grow year year quarter
drug larg satur applic cf patient
market lower growth expect futur
orkambi address larger cf patient popul
two copi mutat gener
growth year year look forward assum
success regulatori approv launch tezacaftor/
kalydeco key driver better penetr rate
patient popul minim inventori stock
fourth quarter may weigh first-quart sale growth
model acceler growth overal thank
anticip launch tezacaftor/kalydeco
continu uptak kalydeco orkambi pediatr
popul compani transit well past
prerevenu day expect greater oper leverag
support bottom line despit increas research
develop spend support pivot trial
alreadi high expect vertex tripl
combin drug regimen hard-to-treat cf patient
popul one mutat one
mutat result minim cftr protein function
vertex comprehens clinic trial strategi derisk
program corrector drug four option
plan advanc phase studi
thank
combin tezacaftor/kalydeco appear
efficaci combo preliminari basi
slate begin first half year meanwhil
compani expect progress anoth set pivot
studi combin tezacaftor deuter
kalydeco once-daili drug regimen --
durat trial still air howev
base past commentari model market entri
triple-combo drug regimen two superb molecul
hand think compani well-posit captur
next largest set cf patient
valuat growth profit oct
rais fair valu estim vertex
per share reflect robust uptak orkambi
kalydeco cystic fibrosi patient certain mutat
valuat rest firm cystic fibrosi program
pipelin ramp-up orkambi approv
next-gener combo tezacaftor kalydeco present
largest near-term opportun vertex
biggest driver model homozyg
popul repres roughli cf patient
assum lower net price discount
 outsid larger
patient popul repres opportun
peak sale though expect near-term
headwind orkambi penetr tezacaftor
second-largest
heterozyg popul cystic fibrosi patient
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
growth next five year driven primarili
blockbust sale cf franchis think rise
product sale propel firm profit
ultim drive oper margin
return invest capit near
bull case consid impact increas
annual price orkambi upcom triplet regimen
rais probabl triplet approv
heterozyg patient group increas
probabl approv rest vertex non-cf
pipelin case fair valu estim increas
per share return invest capit grow well
bear case assum compani combin
therapi difficult-to-treat heterozyg
patient stumbl price pressur caus firm
cut price orkambi futur therapi
case think compani valu would fall per
share return invest capit pressur
approxim
believ vertex current relianc limit rang
market product center one therapeut area
warrant medium uncertainti rate given pipelin
vertex portfolio disease-modifi drug form
basi narrow econom moat rate compani
well-support lengthi patent protect first-mov
statu cystic fibrosi market kalydeco launch
orkambi combin
recent approv disease-modifi
drug market kalydeco orkambi make
backbon cystic fibrosi therapi believ
vertex remain leader rare-diseas space
attribut probabl success tripl
combin regimen kalydeco two corrector
molecul full market launch model
probability-adjust peak sale billion
kalydeco monotherapi larg satur cf
popul gate mutat
howev late-stag competit sight
believ small opportun label expans
margin price increas gener peak sale close
billion vertex proven success expand
drug label genet subtyp includ nearli
potenti cystic fibrosi patient
origin approv price assumpt kalydeco
roughli per year
rest word versu current list price
cord injuri probabl approv less base
earlier stage develop overal think
vertex top line averag compound annual
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
forese futur
given limit treatment option cystic fibrosi
chronic natur diseas vertex abl command
strong price power cours patient life
kalydeco cost close treatment less
cf suffer certain genet mutat
despit aggress price uptak swift
almost elig patient therapi vertex
strategi develop drug known corrector
work combin kalydeco order treat
genet subtyp make larger portion cf
patient orkambi treat peopl common cf
mutat homozyg drug price
per year current target roughli
cf popul pediatr label expans increas
target popul approxim patient
firm cf pipelin drug includ tezacaftor
second-gener corrector
use combin kalydeco
potent treatment difficult-to-treat cf subtyp
next-gener correct would expos vertex
next-largest opportun cf -- het/min patient
compos nearli total cf popul
cf genet disord affect roughli peopl
world-wide caus progress deadli declin
lung function number patient small
six-figur price vertex disease-modifi drug make
megablockbust market potenti addit vertex
cf portfolio experienc welcom commerci
regulatori environ due lack treatment
sever afflict chronic natur therapi limit
competit near-term horizon heighten
market attract patent kalydeco
orkambi extend respect
eu ward gener competit
partnership
remain closest pipelin threat vertex cystic fibrosi
franchis still year away reach market
give vertex time entrench current
cystic fibrosi prescrib
popul also potenti launch second-gener
product element lead us award
compani narrow-moat rate execut
transform rare-diseas powerhous
assign vertex posit moat trend base
promis clinic result pipelin product lack
near-term competit cystic fibrosi allow
domin attract market compani
demonstr abil intern develop success
market drug kalydeco orkambi boost
confid drug candid recent termin
novarti phase potenti drug mean galapago
partner remain major medium-term
threat howev phase candid face sever
year clinic trial need demonstr clearli
superior efficaci and/or safeti profil kalydeco
orkambi order impact vertex commerci
momentum also phase cystic
fibrosi drug ataluren note therapi target
small percentag cf popul
nonsens mutat overlap vertex
beyond cf vertex remain pipelin candid
rel uncertain opportun compani
number pipelin drug target cancer partnership
merck pain spinal cord injuri influenza
partnership johnson johnson earli
say whether prospect becom signific
revenu driver firm believ vertex ampl
potenti diversifi cf portfolio would bolster
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
moat advantag firm exit hepat
 market due incivek precipit declin limit
non-cf pipelin vertex depend cf franchis
key risk posit moat trend opportun
develop anticip howev firm
aggress invest early-stag pipelin beyond cf
enough cash target tuck-on acquisit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
oth firm cystic fibrosi program pois
domin potenti lucr market
forese futur base disease-modifi
potenti drug chronic use patient
overtex track record success launch
drug incivek kalydeco differenti
emerg biotech often falter
commerci
lead drug candid mostli
discov in-hous lend credibl drug-
discoveri technolog potenti gener
overtex valuat rest cf pipelin
misstep bring drug market could limit
compani financi flexibl
oth sky-high price orphan drug like kalydeco
unsustain particularli price-consci european
owhil still rel early-stag increas
competit cf develop pipelin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
year-end vertex billion cash
million credit facil sinc paid
million debtlik leas oblig like
biotechnolog compani vertex histor oper
loss high cost clinic trial
research loss financ larg
offer equiti debt secur collabor
fund arrang develop mileston
royalti partner howev success
launch orkambi kalydeco compani
abl gener signific revenu allow
build signific cash cushion suffici fund
develop commerci remain
development-stag candid even orkambi launch
still ramp expect vertex reach
sustain profit gener signific
cash flow thereaft expect vertex use
cash build diversifi rare diseas portfolio
look beyond cystic fibrosi market
compani futur reli emerg cf franchis
signific amount vertex fair valu hing
commerci success orkambi larg
homozyg patient popul although expect
drug larg captur patient popul
disease-modifi drug market increas
patient discontinu orkambi due bronchospasm
side effect would curtail posit view firm
growth prospect moat trend addit
increas competit cf develop pipelin
could threaten vertex current leadership posit
progress vertex next-gener doublet candid
display bronchospasm effect
help mitig risk similarli assumpt
high price underpin view blockbust potenti
cf market therefor concern payer
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
efficaci
particularli austerity-strap govern europ may
balk high price even drug treat orphan
indic nation institut
excel initi deni reimburs
cost-effect concern hand
kalydeco current price maintain
futur combin therapi much larger
number patient estim may prove
conserv final firm risk compound
early-stag natur remain pipelin
includ experiment treatment influenza pain
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
fidel manag research compani
share
fund
share
fund
rate dr jeffrey leiden becam ceo board
chairman serv compani board
two year previous work presid chief
oper offic abbott laboratori
manag director life scienc ventur capit firm
believ experi particularli stint
pharma asset compani launch
new drug priorit pipelin inde incivek
kalydeco launch quit success
particularli consid commerci issu
commonli affect emerg biotech firm
howev think investor would better serv
compani separ ceo chairman role
addit think manag compens
histor high although recent measur spur
sharehold vote curtail amount go
forward notabl leiden total compens
million sever senior manag
compens packag million leiden
total compens drop million respons
sharehold disapprov previous excess
amount compani also probe sec
seri larg insid stock sale posit clinic news
past year vertex cfo sold
vest hold compani stock surg
promis result cf trial sale
appropri took place prearrang stock-sel
plan question manag long-term prioriti
incent insid abl will sell materi
amount stock rather maintain sharehold
long-term investor
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
ad vertex best idea list share trade
discount fve ahead catalyst
ad vertex best idea listth stock
current trade discount per share
fair valu estim ahead expect approv
tezacaftor/ivacaftor anticip progress
triple-combin program pivot trial earli next
year recent increas fair valu per share
reflect higher-than-expect uptak
orkambi kalydeco sale compani third-quart
earn updat vertex monopoli cystic fibrosi
market form basi narrow moat rate
believ compani remain leader rare-
diseas space forese futur stock saw
meteor rise summer impress first-in-human
result triple-combin drug program
would unlock next largest cystic fibrosi patient
opportun firm howev factor
signific derisk event addit upsid remain
view
addit think market
believ market fulli appreci upsid
like approv next-gener doublet regimen
tezacaftor/ivacaftor expect first-quart
 second half european union
acceler uptak cystic fibrosi
popul serv vertex first-gener drug
still
incorpor regulatori development risk vertex
triple-combin regimen anticip start
pivot trial earli assum approv triple-
combin regimen valuationvertex fewer
four combin choos pivot test
report impress early-stag data limit
pipelin threat compani cystic fibrosi franchis
stock
medium
given posit market dynam think vertex cf
program could grow billion forecast
peopl world-wide six-figur price vertex
disease-modifi drug chronic natur diseas
support megablockbust market potenti
vertex growth prompt fve increas
share under-valued front anticip approv
rais fair valu estim vertex
per share reflect robust uptak orkambi
kalydeco quarter updat sale estim
fall line manag new guidanc billion-
billion full-year orkambi sale billion-
billion million kalydeco
sale million result
updat outlook vertex look under-valued oct
think compani drug portfolio significantli de-
risk follow earlier news posit triple-combo
drug data harder-to-treat cf patient
monopoli cystic fibrosi market merit narrow moat
thank approv kalydeco children age
older residu function mutat drug
sale increas quarter quarter
patient come line believ kalydeco sale return
slow steadi growth phase data evalu next-
combin
kalydeco show acut effect lung-
function kalydeco patient howev patient
alreadi well-serv kalydeco believ
find bear signific model estim
orkambi target patient two copi
mutat grew past quarter approv
children age support sale expans
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
expect approv children age provid modest
tailwind expect approv next-gener
orkambi tezacaftor ivacaftor first quarter
 second half eu
anticip captur larger share patient
homozyg mutat tezacaftor ivacaftor
show bronchoconstrict side effect seen
orkambi could discourag modest number
patient continu orkambi therapi
vertex enac inhibitor found add
increment improv top orkambi treatment
phase trial prompt compani record
impair asset quarter could
built larger barrier entri pipelin competitor
write-off asset affect valuat
believ stock alreadi incorpor
anticip approv triple- combin therapi
heterozygous-minim function het-min cf popul
howev confirm drug cocktail efficaci
subsequ approv would elimin concern
regulatori risk expect provid futur upsid
stock view assum regimen reach
market model read-out addit
phase data test multipl next-gener corrector
tripl regimen earli vertex begin pivot
test combin inclus
once-daili version kalydeco twice-daili
acquir concert pharma materi
estim vertex het/min opportun success
integr molecul tripl regimen would
build compani competit posit beyond cf vertex
need bolster pipelin next opportun
expect firm make small acquisit protect
cf franchis build portfolio early-stag candid
next era
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
